Valneva (NASDAQ:VALN) Price Target Cut to $14.00 by Analysts at Guggenheim

Valneva (NASDAQ:VALN) had its price target reduced by Guggenheim from $15.00 to $14.00 in a research report released on Thursday morning,Benzinga reports. Guggenheim currently has a buy rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $17.00 price target on shares of Valneva in a research report on Tuesday, April 15th.

Valneva Trading Up 1.4 %

NASDAQ VALN opened at $6.47 on Thursday. The company’s fifty day simple moving average is $6.76 and its 200-day simple moving average is $5.75. The stock has a market cap of $541.12 million, a P/E ratio of -49.77 and a beta of 1.85. Valneva has a 52 week low of $3.62 and a 52 week high of $9.50. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70.

Valneva (NASDAQ:VALN) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.27. The company had revenue of $51.79 million during the quarter, compared to analysts’ expectations of $41.80 million. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. Equities research analysts predict that Valneva will post 0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Wells Fargo & Company MN raised its position in shares of Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock valued at $1,079,000 after acquiring an additional 30,859 shares in the last quarter. ABC Arbitrage SA acquired a new stake in shares of Valneva during the fourth quarter worth $84,000. Finally, GAMMA Investing LLC bought a new position in shares of Valneva in the 1st quarter worth about $94,000. Institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.